Warren Huff - Reata Pharmaceuticals Chairman of the Board and Presidentident, CEO

RETADelisted Stock  USD 109.67  3.31  2.93%   

Chairman

Mr. J. Warren Huff is Chairman of the Board, President, Chief Executive Officer of Reata Pharmaceuticals Inc. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology startup enterprises. Mr. Huff started his career as an attorney with Johnson Gibbs, P.C., where he was a partner and Chairman of the Corporationrationrate Securities Practice since 2015.
Age 69
Tenure 9 years
Phone972 865 2219
Webhttps://www.reatapharma.com
Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University. Our Board believes that Mr. Huff is qualified to serve on our Board due to his extensive experience investing and working in the pharmaceuticals industry.

Reata Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Reata Pharmaceuticals currently holds 119.46 M in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Reata Pharmaceuticals has a current ratio of 10.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reata Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 1 records

CHAIRMAN Age

Allan JacobsonPTC Therapeutics
78
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. Reata Pharmaceuticals (RETA) is traded on NASDAQ Exchange in USA and employs 321 people.

Management Performance

Reata Pharmaceuticals Leadership Team

Elected by the shareholders, the Reata Pharmaceuticals' board of directors comprises two types of representatives: Reata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reata. The board's role is to monitor Reata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Warren Huff, Chairman of the Board and Presidentident, CEO
Christian Wigley, VP Officer
Bhaskar Anand, VP Officer
Michael Wortley, Vice President Chief Legal Officer
Dawn Bir, Chief Commercial Officer
Colin MD, Ex Officer
Manmeet Soni, CFO COO
Elaine Castellanos, Consultant
Steve Harman, VP Officer
Dakota Gallivan, VP Officer

Reata Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Content Syndication
Quickly integrate customizable finance content to your own investment portal